Review article: the investigation and management of gastric neuroendocrine tumours
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary: Background: Gastric carcinoids (GC s) or neuroendocrine tumours (NET s) are increasingly identified at endoscopy, and account for 0.6–2% of all gastric polyps identified. The SEER database in the US has demonstrated a rising incidence of gastric NET s amongst all NET s; from 2.2% between 1950 and 1969 to 6.0% between 2000 and 2007. Aim: To review the literature and assist clinicians in managing patients with GC s. Methods: A literature search was conducted through MEDLINE using search terms: gastric, carcinoid, neuroendocrine tumour, therapy, endoscopy, mucosal resection, submucosal dissection. Relevant articles were identified through manual review. The reference lists of these articles were reviewed to include further appropriate articles. Results: There are three types of GC s with important epidemiological, pathophysiological, histological and endoscopic differences that affect prognosis and management. Type 1 and 2 GC s develop in the context of hypergastrinaemia that originates from achlorhydria in atrophic gastritis and a gastrinoma, respectively. Type 3 GC s occur sporadically and independent of gastrin. The histological type, grade and Ki67 index are used to determine prognosis and direct clinical management. Type 1 GC s >1 cm in size and type 2 GC s should be assessed for invasion beyond the submucosa with EUS prior to endoscopic resection with EMR or ESD. Type 3 GC s should be managed as per recommendations for gastric adenocarcinoma. The treatment of advanced disease is multimodal. Conclusions: Patients with gastric carcinoids should be discussed in a specialist neuroendocrine tumour multidisciplinary meeting to ensure all treatment options are explored in localised and advanced disease. Areas of controversy exist that need further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms
Delle Fave, G., Kwekkeboom, D. J., Van Cutsem, E., Rindi, G., Kos-Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., & Ruszniewski, P. (2012) · Neuroendocrinology · doi:10.1159/000335595 · Cited by 327 · cited 1×
“There are important epidemiological, pathophysiological, endoscopic and histological differences between each type that affects prognosis, management and follow-up.(7)”
BackgroundGibril, F., Schumann, M., Pace, A., & Jensen, R. T. (2004) · Medicine · doi:10.1097/01.md.0000112297.72510.32 · Cited by 313
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate
Merola, E., Sbrozzi-Vanni, A., Panzuto, F., D’Ambra, G., Di Giulio, E., Pilozzi, E., Capurso, G., Lahner, E., Bordi, C., Annibale, B., et al. (2012) · Neuroendocrinology · doi:10.1159/000329043 · Cited by 132 · cited 1×
“Nonlesion gastric biopsies identify atrophy in 82% of patients, with severe atrophy found in 64%.(45) Gastric pH testing (>4) can help differentiate type 1 GCs in cases where atrophy is not readily demonstrated.”
BackgroundProton pump inhibitors and gastric neoplasia: Figure 1
Kuipers, E. J. (2006) · Gut · doi:10.1136/gut.2005.090514 · Cited by 115
Defining surgical indications for type I gastric carcinoid tumor
Gladdy, R. A., Strong, V. E., Coit, D., Allen, P. J., Gerdes, H., Shia, J., Klimstra, D. S., Brennan, M. F., & Tang, L. H. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0687-y · Cited by 112
Vannella, L., Sbrozzi-Vanni, A., Lahner, E., Bordi, C., Pilozzi, E., Corleto, V. D., Osborn, J. F., Delle Fave, G., & Annibale, B. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04659.x · Cited by 109
Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
Jianu, C. S., Lange, O. J., Viset, T., Qvigstad, G., Martinsen, T. C., Fougner, R., Kleveland, P. M., Fossmark, R., Hauso, Ø., & Waldum, H. L. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.627444 · Cited by 80
Cited by
The role of endoscopy in the management of premalignant and malignant conditions of the stomach
Evans, J. A., Chandrasekhara, V., Chathadi, K. V., Decker, G. A., Early, D. S., Fisher, D. A., Foley, K., Hwang, J. H., Jue, T. L., Lightdale, J. R., et al. (2015) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2015.03.1967 · Cited by 304
“Five- and 10-year survival of patients with type 1 gastric carcinoid is no different from that of the general population,(70) and clinical management is not well defined because both endoscopic surveillance alone and polypectomy with surveillance have been advocated.(68,69,71) Type 2 gastric carcinoids affect men and…”
Background
Metadata
- Authors
- Basuroy, R., Srirajaskanthan, R., Prachalias, A., Quaglia, A., & Ramage, J. K.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-03-13
- Volume
- 39
- Issue
- 10
- Pages
- 1071-1084
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2169555547
- Cited by
- 180
- References
- 8
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.